Dishman Carbogen Amcis Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/jnsggx87ucdyz6z7ffbp8mxc.pdf

Key Takeaways


The Turnaround Narrative

Pascal Villemagne: "we finally tackle all the issues we are facing, and we have definitely turned the corner"

India CRAMS: The Reopened Engine

Harshil Dalal: "So, now because the changes that have been made between the Bavla and the Naroda site, including the operational excellence that has been brought in both sites put together can do a revenue on the existing asset base of close to about Rs. 1,000 crores."

Dutch Entity: The Margin Problem


Goodwill Accounting Change


French Facility Ramp-Up


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth~10% incremental revenue over FY24FY25 full year
EBITDA margin~18% for the full year; remaining three quarters must run above 18% to achieve thisFY25 full year
Dutch raw material cost reliefRenegotiated wool grease contract reduces cost; high-cost inventory clears by Q2 endFrom Q3 FY25
French entity lossFull-year loss of ~€5 million, smaller than FY24FY25 full year
India CRAMS revenueRs. 325–350 croresFY25 full year
Long-term EBITDA marginReturn to 25–26%Next 2 to 3 years
Goodwill amortizationReduced to ~Rs. 6 crores per annum, tested for impairment annuallyEffective 1 April 2024

Key Metrics

MetricQ1 FY25
Revenue₹591 cr (per an analyst's math), down from ₹723 cr in Q1 FY24; average quarterly revenue ₹600–₹650 cr
India CRAMS revenue₹82 cr, +114% YoY from ₹38 cr in Q1 FY24
India CRAMS EBITDA margin~14%, turned positive
Netherlands revenue-16% YoY, largely due to lower vitamin D analogue sales
French entity revenue€1.2 million, operations began June 2024
French entity EBITDA impact-€2.5 million in Q1; full-year FY25 expected at -€5 million
Material cost₹60 cr, lower due to high-margin commercial projects sold in Q1
Finance cost₹32 cr, in line with last year
Exceptional item₹5 cr, write-off of non-usable inventory
Goodwill amortization~₹6 cr per annum, reduced from ~₹45 cr; useful life changed to 99 years effective 1 Apr 2024
Net debtCHF 16.4 cr as of 30 Jun 2024
Swiss entity development vs commercial mix40% development, 60% commercial in Q1; historically 55–60% development
Dutch entity product mix~60% cholesterol, ~40% vitamin D analogues in Q1; historically ~55% vitamin D, ~45% cholesterol
FY25 revenue growth guidance~10% incremental revenue over FY24
FY25 EBITDA margin guidance~18% for the full financial year
Swiss entity capacity utilization~85%, can reach 90–95%
Dutch entity capacity utilization~65–70%
India CRAMS revenue potential~₹1,000 cr on existing asset base; FY24 revenue ~₹250 cr